BP 14979

Drug Profile

BP 14979

Alternative Names: BP 1.4979; BP1 4979

Latest Information Update: 17 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioprojet
  • Class Smoking cessation therapies
  • Mechanism of Action Dopamine D3 receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Smoking withdrawal

Most Recent Events

  • 22 Nov 2017 Bioproject plans a phase II trial for Restless legs syndrome in France in January 2018 (NCT03345953)
  • 17 Mar 2016 Phase-II development is ongoing in France, Poland and Czech Republic
  • 01 Mar 2013 Phase-II clinical trials in Smoking withdrawal in Czech Republic (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top